By Fineline Cube 
Singapore-based Mirxes Group (HKG: 2629) announced on July 23, 2025, that it has entered into a strategic partnership with Japan’s NAGAWA Pharmaceutical Co., Ltd. to launch a “10,000-person free gastric cancer screening” public welfare project in Japan. The initiative targets elderly individuals and high-risk groups with Helicobacter pylori infections. This collaboration aims to promote the clinical application of Mirxes’ GASTROClear miRNA blood test and establish a localized early cancer screening ecosystem in Japan.
Collaboration Details
The partnership leverages Mirxes’ miRNA detection platform and NAGAWA’s expertise in manufacturing, distribution, and technology transfer. The project will focus on Mirxes’ GASTROClear for gastric cancer and LUNGClear for lung cancer, aiming to develop non-invasive, highly accurate early screening solutions.
GASTROClear’s Regulatory and Clinical Milestones
GASTROClear has received regulatory approvals in Singapore and the European Union, positioning it as the world’s first molecular screening IVD product for gastric cancer. Additionally, it has completed a prospective clinical trial involving nearly 10,000 participants in China. Its non-invasive and time-efficient nature makes it particularly suitable for frail, elderly, or chronically ill individuals who may find endoscopic examinations challenging.-Fineline Info & Tech